Platelets' glycoproteins and their ligands in patients with intermittent claudication

International Angiology

Volumn 22, Issue 2, 2003, Pages 164-171

  Gosk Biersaka, I ^a   Adamiec, R ^a   Szuba, A ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Fibrinogen; GPII b IIIa, complex; Peripheral vascular disease; Platelet activation; Platelet glycoprotein; Platelet glycoprotein GP Ib IX complex; von Willebrand factor

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; LIGAND; LIPID; MONOCLONAL ANTIBODY; THROMBIN RECEPTOR; THROMBOCYTE RECEPTOR; URIC ACID; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; THROMBOCYTE;

ADULT; AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; FEMALE; FIBRINOGEN; HUMANS; INTERMITTENT CLAUDICATION; LIGANDS; MALE; MIDDLE AGED; PLATELET MEMBRANE GLYCOPROTEINS; SMOKING; STATISTICS; TRIGLYCERIDES; URIC ACID; VON WILLEBRAND FACTOR;

EID: 0037591291     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon J, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-20.
2. Zeller JA, Tschoepe D, Kessler Ch. Circulating platelets show increased activation in patients with acute cerebral ischaemia. Thromb Haemost 1999;81:373-7.
3. Pirice DT, Loscalzo J. Cellular adhesion molecules and atherosclerosis. Am J Med 1999;107:85-96.
4. Chow TW, Hellums JD, Moake JL, Kroll MH. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium infux associated with aggregation. Blood 1992;80:113-20.
5. Ginsberg MH, Du X, O'Toole TE, Loftus JC. Platelet integrins. Thromb Haemost 1995;74:352-9.
6. Coller BS, Peerschke EI, Scudder LE, Sullivan Ca. A murine monoclonal antibody that completly blocks the binding of fibrinogen to platelets produces a thrombastenic-like stste in normal platelets and binds to glycoproiein II b and/or IIIa. J Clin Invest 1983;72:325-38.
7. Clemetson KJ. Platelet GPIb-IX compex. Thromb Haemost 1997;78:266-70.
8. Koksch M, Zeiger F, Witting K, Pfeiffer D, Ruehlmann Cal. Haemostatic derangement in advanced peripheral occlusive arterial disease. Int Angiol 1999;18:256-62.
9. Zeiger F, Stephan S, Hoheisel G, Pfeiffer D, Ruehlmann C, Koksch M. P-selectin expression, platelet aggregates and platelet- derived microparticle formation are incereased in peripheral arterial disease. Blood Coagul Fibrinol 2000;11:723-8.
10. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity in peripheral atherosclerosis flow mediated platelet function is a sensitive and specific disease indicator. Int Angiol 1996;15:335-43.
11. Devine DV, Andestad G, Nugent D, Carter CJ. Platelet associated factor XIII as a marker of platelet activation in patients with peripheral vascular didsease. Arterioscler Thromb 1993;13:857-62.
12. Reginelli JP, Topol EJ. Glycoprotein II b/IIIa inhibitors: current indications and future prospects. Am J Med 2000;109:252-4.
13. Knight CJ, Panesar M, Wright C, Clarke D, Butowski PS, Patel D et al. Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age. Arterioscler Thromb Vasc Biol 1997;17:2044-53.
14. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101:479-86.
15. Vila V, Martinez Sales V, Reganon E, Aznar J. The effect of thrombin on the dynamic exchange between intraplatelet and extrapaltelet fibrinogen. Br J Haematol 1997;99:548-54.
16. Simmons SR, Sims PA, Albrecht RM. Alpha IIb beta3 redistribution triggered by receptor cross-linking. Arterioscler Thromb Vasc Biol 1997;17:3311-20.
17. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cariovascular disease. The Framingham Sudy. JAMA 1987;258:1183-6.
18. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinoge, cigarette smoking and risk of cariovascular disease: insigths from the Framingham Study. Am Heart J 1987;113:1006-10.
19. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J 1998;19 Suppl A:A53-61.
20. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990;227:273-8.
21. Ruggeri ZM, Ware J. The structure and function of von-Willebrand factor. Thromb Haemost 1992;67:594-9.
22. Rand JH, GlanVille RW, WU XX, Ross JM, Zangari M, Gordon RE et al. The significance of subendothelial von Willebrand factor. Thromb Haemost State of the Art 000;78:445-50.
23. Peterson DM, Stathopoulos NA, Giorgio TD, Hellums JD, Moake JL. Sheare-induced platelet aggregation requires von Willebrand factor and platelet membranae glycoproteins I b and IIb/IIIa. Blood 1987;69:625-8.
24. Blann AD, Dobrotova M., Kubisz P, Mc Collum CN. von Willebrand factor, sluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost 1995;74:626-30.
25. Smith FB. von Willebrand factor, beta-thromboglobulin and platelet activation. In: Fowkes FGR, edition. Epidemiology of Peripheral Vascular Disease. London: Springer; 1991.p.271-83.
26. Blann AD, Seigneur M, Adams RA, McCollum CN. Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis. Eur J Vasc Endovasc Surg 1996;12:218-22.
27. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. For the European Concerted Action on Thrombosis and disabilities angina pectoris study group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
28. Smith FB, Lowe GD, Fowkes FGR, Rumley A, Rumley AG, Donnan PT et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993;102:155-62.
29. Holvoet P, Collen D. Thrombosis and atherosclerosis. Curr Opin Lipidol 1997;8:320-8.
30. Pedreno J, Fernandez R, Cullare C, Barcelo A, Elorza- MA, de-Castellarnau C. Platelet integrin alpha IIb beta 3 (GPIIb-IIa) is not implicated in the binding of LDL to intact resting platelets. Arterioscler Thromb Vasc Biol 1997;17:156-63.
31. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kicler TS, Becker LC. A polimprphism of a platelet glycoprotein receptor as an inherided risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090-5.
32. Gonzalez Conejero R, Lozano ML, Rivera J, corral J, Iniesta JA, Moraleda SM et al. Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood 1998;92:2771-6.
33. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997;28:1392-5.
34. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis Lancet 1997;349:385-8.
35. Herrmann SM, Poirier O, Marques Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The Leu33/Pro polymorphism (PlA1/PlA2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. Etude Cas-Temoins de l'Infarctus du Myocarde. Thromb Haemost 1997;77:1179-81.
36. Coller BS. Platelet GP II b/IIIa antagonists :pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-5.
37. Mousa SA, Mu DX, Lucchesi BR. Prevention of carotid artery thrombosis by oral platelelet GP II b/IIIa antagonist in dogs. Stroke 1997;28:830-6.
38. Golino P, Ragni M, Cirillo P, Pascucci I, Ezekowitz MD, Pawashe A et al. Aurintricarboxylic acid reduces platelet deposition in stenosed and endothelially injured rabbit carotid arteries more effectively than other antiplatelet interventions. Thromb Haemost 1995;74:974-9.